CJC-1295 with DAC vs. No DAC

Start with the naming, because it is genuinely wrong

CJC-1295 was described in the literature as a bioconjugate: a modified GRF(1-29) peptide carrying a linker that binds covalently to circulating albumin. The Drug Affinity Complex — DAC — is not an accessory to CJC-1295. It is the thing that made the molecule novel enough to name.

'CJC-1295 no DAC' is therefore a market coinage rather than a literature term. What it refers to is tetrasubstituted GRF(1-29) — the same peptide backbone with the four stabilising substitutions, minus the conjugating linker. In the older research and forum literature that molecule is called Mod GRF 1-29, and that is the more accurate name.

What the DAC actually is

The DAC is a maleimidopropionyl group attached to the peptide at the lysine in position 30. Maleimide chemistry is specific: it reacts with free thiols. In blood plasma the dominant free thiol is cysteine-34 of serum albumin, which is unusually accessible and unusually abundant. The conjugate forms in circulation, covalently, and the peptide is thereafter carried on albumin.

That is the whole mechanism of the extension, and it explains the size of the effect. Albumin has a circulating half-life of roughly three weeks. A peptide covalently attached to it inherits a substantial share of that persistence, rather than the minutes a free peptide of this size would get.

Side by side

One figure in that table deserves a caveat. The six-to-eight day half-life for the DAC form comes from the published human pharmacokinetic study and is well sourced. The roughly-thirty-minute figure for the No-DAC form circulates widely without a strong primary source behind it, and should be treated as an approximation of unclear provenance rather than a measured value.

The interesting question: what continuous stimulation does

Growth hormone is not secreted at a steady rate. It is released in pulses, with the pattern of those pulses — amplitude, frequency, and the depth of the troughs between them — carrying biological information distinct from the total amount released. A compound that holds GHRH receptor stimulation elevated for days therefore raises an obvious question: does it flatten the pulses?

Ionescu and Frohman addressed exactly this in 2006. Under continuous stimulation from the DAC conjugate, pulsatile secretion persisted — the underlying rhythm was not abolished. What changed was the baseline: trough and mean concentrations rose, with the pulse pattern superimposed on the higher floor.

This is the single most useful published finding about the DAC form, and it is the one most often skipped. It reframes the comparison from 'long versus short' to 'raised floor versus discrete peaks' — two different shapes of receptor exposure, not two speeds of the same thing.

Why this is not a preference question

It is tempting to conclude that one exposure pattern must be preferable. The literature does not support that conclusion in either direction. No published study compares the two forms head-to-head on any endpoint. The pulsatility finding tells you what the DAC form does to the secretion pattern; it does not establish that either pattern is better for anything.

What can be said is narrower and more useful: they are pharmacologically different inputs to the same receptor, and a study using one does not characterise the other.

Stability, and a quality issue specific to the DAC form

The conjugating chemistry that defines the DAC form is also its main quality liability. Maleimide groups hydrolyse in aqueous conditions, and a hydrolysed maleimide cannot form the thioether bond with albumin. Material that has been poorly manufactured, poorly dried, or held in solution before use may retain the correct peptide sequence and an acceptable purity figure while having lost the very property that distinguishes it.

That failure mode is effectively invisible to the assays usually reported on a certificate of analysis. A purity percentage and a molecular weight will not tell you whether the linker is intact — and it is precisely why residual moisture in the lyophilized cake matters more for this construct than for a plain peptide. The No-DAC form has no such liability: it is a conventional peptide and behaves like one.

Handling is otherwise the same across both: reconstitution with bacteriostatic water, lyophilized material at −20 °C, reconstituted solution at 2–8 °C and protected from light. The Aurum Bio catalogue lists the No-DAC form.

The short version

• The DAC is the defining feature of CJC-1295, not an add-on. 'No DAC' is a market name for Mod GRF 1-29.
• The linker binds covalently to cysteine-34 on albumin, which is why the half-life jumps from minutes to days.
• Continuous stimulation did not abolish pulsatile secretion in the published human study; it raised the baseline underneath it.
• No head-to-head study compares the two forms, so neither exposure pattern is established as preferable.
• For DAC material, linker integrity is a real and hard-to-detect quality risk that standard purity reporting does not cover.